Clear All
796 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J2354 octreotide sandostatin 25 mcg Hormonal Therapy Somatostatin Analog No 1998 Jan 1, 2004 In Use
NA Glasdegib Daurismo 25mg, 100mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2018 In Use
Q2055 Idecabtagene vicleucel Abecma 460 million Immunotherapy CAR-T BCMA No 2021 Jan 26, 2022 In Use
J9228 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jan 1, 2012 In Use
J9281 Mitomycin Pyelocalyceal Instillation Jelmyto 1mg Chemotherapy Antitumor Antibiotic Alkylating Agent/Mitomycin No 2020 Jan 1, 2021 In Use
NA Nintedanib Ofev 150 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
C9205 Oxaliplatin Eloxatin unspecified Chemotherapy Alkylating Agent Platinum Compound No 2002 Jul 1, 2003 Dec 31, 2005 No Longer Used
J9258 Paclitaxel (Teva) Paclitaxel 1mg Chemotherapy Antimitotic Agent Taxane No 2016 Dec 7, 2023 Sep 14, 2024 No Longer Used
NA tretinoin Vesanoid 10 mg Hormonal Therapy Immunomodulator Retinoic Acid Derivative Yes 1995 In Use
NA venetoclax Venclexta 100 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
J9150 Daunorubicin Daunorubicin Hydrochloride 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1996 Jan 1, 1986 In Use
J9002 Doxorubicin Doxil 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1995 Jan 1, 2013 Dec 31, 2013 No Longer Used
C9307 Linvoseltamab-gcpt Lynozyfic 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2025 Jan 12, 2026 Mar 18, 2026 In Use
J8650 Nabilone Cesamet 1 mg Ancillary Therapy Antiemetic Cannabinoid Yes 1985 Jan 1, 2007 In Use
J9302 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Jan 1, 2011 In Use
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan 1, 2019 In Use
NA Rucaparib Rubraca 250 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
Q5146 Trastuzumab-strf (hercessi) Hercessi 10mg Immunotherapy Monoclonal Antibody HER2 No 2025 Jan 1, 2025 In Use
J9097 Cyclophosphamide Cyclophosphamide lyophilized 2 g Chemotherapy Alkylating Agent Nitrogen Mustard No 1959 Jan 1, 1994 In Use
Q5136 Denosumab-bbdz Jubbonti/Wyost 1mg Immunotherapy Monoclonal Antibody RANKL No 2024 Sep 11, 2024 In Use
NA Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 No 2015 In Use
C9426 Floxuridine Floxuridine 500 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1970 Jan 1, 2004 Dec 31, 2005 No Longer Used
NA Pralsetinib Gavreto 100mg Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Yes 2020 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.